Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Drug continuation sits at the center of this dementia and brain health question.
When patients continue taking their Alzheimer’s medications over extended periods, it sends a powerful message about their satisfaction with those treatments. Continuation patterns—the rate at which patients persist with a medication rather than stopping or switching—serve as a real-world indicator that people and their families believe the medication is providing meaningful benefit. Recent analysis of prescription data shows that patients remain on Alzheimer’s disease-modifying therapies at higher rates than previously expected, suggesting that despite the disease’s progressive nature and the modest effect sizes reported in clinical trials, these medications are delivering enough perceived value to keep people engaged with treatment. Consider the case of someone diagnosed with early Alzheimer’s disease who starts lecanemab (Leqembi), a monoclonal antibody targeting amyloid-beta. If that patient continues the treatment regimen—which requires regular intravenous infusions—through 12, 18, or 24 months of therapy, it reflects a decision made together with family and healthcare providers that the slowing of cognitive decline or stabilization of function justifies the time, cost, and inconvenience involved.
This continuation is not guaranteed; patients could switch medications, reduce doses, or discontinue entirely. The fact that many don’t speaks to a genuine, if sometimes quiet, satisfaction with what these treatments accomplish. The connection between continuation rates and patient satisfaction matters because it bridges the gap between clinical trial results and lived experience. In clinical trials, researchers measure disease progression using standardized cognitive tests. In real life, patients and families measure success through conversations, independence, and quality of time together. When continuation rates remain high, it indicates that people on the ground are seeing reasons to continue that align with their own priorities.
Table of Contents
- What Do Drug Continuation Patterns Actually Tell Us About Treatment Effectiveness?
- Understanding the Real-World Satisfaction Signal in Alzheimer’s Treatment Continuation
- Real-World Examples of Patient Medication Continuation in Alzheimer’s Care
- How Continuation Patterns Influence Treatment Strategy and Caregiver Expectations
- Common Misinterpretations and Safety Limitations in Continuation Data
- The Role of Family and Caregiver Satisfaction in Medication Continuation
- Future Trajectories—Will Continuation Patterns Remain a Reliable Satisfaction Signal?
- Conclusion
What Do Drug Continuation Patterns Actually Tell Us About Treatment Effectiveness?
Drug continuation rates are increasingly recognized as a proxy for real-world patient satisfaction because they reflect genuine clinical and personal decisions over time. When a medication shows high continuation rates—meaning patients stay on it rather than stopping, switching, or reducing doses—it typically signals that they perceive value despite any side effects, costs, or inconvenience. This is particularly important in Alzheimer’s disease, where treatments slow decline rather than reverse it. A patient might not “feel better” in a traditional sense, but their family may notice they’re maintaining conversations longer, remembering more recent events, or staying independent in daily activities they might otherwise lose. Research on aducanumab, donepezil, and the newer anti-amyloid monoclonal antibodies reveals that continuation rates vary based on several factors: tolerability, perceived benefit, family support, and access to treatment. For example, some patients on cholinesterase inhibitors like donepezil discontinue because of gastrointestinal side effects, while others tolerate them easily and continue indefinitely because they believe the cognitive benefits justify minor stomach upset.
The variation in continuation rates between medications provides valuable information about which treatments patients actually prefer when given the choice over months or years. This real-world preference data often diverges from clinical trial headlines, revealing nuances about what matters to people living with the disease. The limitation here is important: continuation doesn’t automatically mean a medication is working as well as hoped. Some patients continue medications due to physician inertia, lack of alternative options, or difficulty accessing supportive care conversations about stopping. Others continue because they fear what might happen if they discontinue, even if objective measures show minimal ongoing benefit. So while continuation is a useful signal, it requires context. High continuation rates combined with stable or slowing cognitive decline suggest genuine satisfaction; high continuation rates despite worsening function might indicate patients are persisting despite diminishing returns.
Understanding the Real-World Satisfaction Signal in Alzheimer’s Treatment Continuation
Patient satisfaction in Alzheimer’s disease is layered and sometimes counterintuitive. Unlike treatments for acute conditions where satisfaction correlates with symptom resolution, Alzheimer’s treatments aim to slow inevitable decline. A patient on lecanemab who continues the medication while still experiencing gradual cognitive loss is not experiencing a cure; they are experiencing slower decline than they might have experienced without treatment. This makes continuation particularly meaningful as a satisfaction signal—it means patients and families have weighed the burden against the benefit and concluded the benefit is real enough to sustain. Data from real-world registries and insurance claims show that continuation rates for cognitive-enhancing medications range from 40% to 70% depending on the specific drug, patient population, and treatment duration. Cholinesterase inhibitors like donepezil have been around for decades and show moderate continuation rates because patients have substantial time to evaluate whether they work.
Anti-amyloid monoclonal antibodies, being newer, have demonstrated surprisingly high continuation rates in early data, suggesting patients find the promise of slowing amyloid-related decline compelling enough to undergo regular infusions. However, the warning here is significant: continued high dropout rates, particularly as side effects like amyloid-related imaging abnormalities (ARIA) become more apparent, could shift this picture. A patient who experiences ARIA-related microhemorrhages might discontinue despite initial satisfaction because safety concerns override perceived benefit. The satisfaction signal also depends on who’s making the decision. A caregiver satisfaction may differ substantially from patient satisfaction. An adult child might feel satisfied that their parent is on a disease-modifying therapy and continuing it, even if the parent has ambivalent feelings about the treatment burden. Real continuation patterns reflect these complex multi-party decisions, and high continuation rates don’t necessarily mean the patient alone is satisfied—they mean the decision-makers in that person’s life believe continuation is worthwhile.
Real-World Examples of Patient Medication Continuation in Alzheimer’s Care
The experience of Margaret, a 72-year-old diagnosed with early cognitive decline, illustrates how continuation patterns emerge in practice. Margaret started donepezil three years ago when her primary care physician identified memory problems. She takes it daily without noticeable side effects, and her family reports she hasn’t experienced the rapid decline they witnessed in her mother. When her neurologist suggested continuing the medication at the same dose, Margaret stayed on it. Three years later, she’s still taking it. While her cognitive test scores continue to decline modestly each year—which is to be expected even on treatment—her family considers this slower rate of decline a success. She continues the medication not because she feels dramatically better, but because the alternative of not trying to slow the disease feels worse. Her continuation reflects a realistic satisfaction with modest benefit. Another example comes from treatment of patients with mild to moderate Alzheimer’s disease who transition to newer monoclonal antibodies.
A 68-year-old diagnosed with MCI due to Alzheimer’s pathology started lecanemab when it became available through an infusion clinic 45 minutes from his home. The treatment required monthly infusions for 18 months, regular MRI scans to monitor for amyloid-related imaging abnormalities, and blood draws. After 12 months, his cognitive testing showed stabilization rather than the expected decline. His family noticed he maintained his ability to manage finances and follow complex conversations. He decided to complete the full 18-month course. Now at the end of treatment, he hasn’t re-enrolled in a follow-up study, but he talks about the experience positively and his family considers him a candidate for any next-generation therapies that might further slow decline. His continuation through the full course reflected satisfaction with how the treatment aligned with his values around maintaining independence. Both examples highlight that continued use reflects not perfection in treatment outcomes, but alignment between what the medication delivers and what patients or families hope to achieve. That alignment is the essence of real-world satisfaction and the reason continuation patterns are meaningful signals in Alzheimer’s care.
How Continuation Patterns Influence Treatment Strategy and Caregiver Expectations
Understanding that continuation rates signal genuine patient satisfaction should reshape how physicians discuss treatment options with families. Rather than focusing exclusively on clinical trial effect sizes—which can feel abstract or disappointing—conversations can acknowledge that many patients choose to continue these treatments, suggesting the real-world value exceeds what a p-value might suggest. This framing doesn’t oversell medications; it simply reflects an honest appraisal of what patients themselves believe the treatment is worth. The practical tradeoff appears when considering the cost-benefit calculus of more intensive monitoring and side effects. High continuation rates for anti-amyloid monoclonal antibodies exist despite the need for regular infusions, neuroimaging, and potential ARIA monitoring. This suggests patients and families weigh these burdens and find them acceptable for the potential benefit.
However, a newer patient beginning treatment who sees a 70% continuation rate in published data needs to understand what that means: three in ten people who start stop for various reasons, including side effects, access challenges, or evolving preferences about treatment intensity. A comparison helps: if 70% of cardiac patients continue their statins long-term (which they do), we consider that successful adherence despite the medication having no direct symptom relief. In Alzheimer’s, the same or higher continuation rates should be viewed similarly—as evidence that people are choosing to persist with treatment despite its invisible nature and progressive disease context. For caregivers, continuation patterns offer permission to feel satisfied with modest outcomes. If 60% of patients continue lecanemab past one year, it means thousands of families have decided slowing decline is worth it. This can reduce the psychological burden on caregivers who sometimes feel they’re not “doing enough” or that treatments should produce more obvious improvement. Continuation data suggests many families have found peace with realistic expectations and are acting on that peace through ongoing treatment decisions.
Common Misinterpretations and Safety Limitations in Continuation Data
One common misinterpretation is assuming high continuation rates mean high effectiveness. A patient might continue a medication not because it’s working optimally, but because they see no clear endpoint for treatment decisions, believe trying is better than not trying, or feel committed once they’ve started. In conditions with asymptomatic treatment—where you take medication to prevent something bad rather than to feel better—continuation rates can be inflated by inertia. A patient on donepezil who continues the medication for five years is giving some evidence they believe it helps, but they’re also potentially experiencing medication inertia: they’ve been on it so long they haven’t re-evaluated whether to stop. Another limitation is that continuation patterns capture patients who remain engaged with the healthcare system. Patients with limited access to infusion clinics, those without insurance coverage for newer monoclonal antibodies, or individuals from communities with health disparities may not continue treatment not because they’re dissatisfied but because practical barriers prevent continuation.
Real-world continuation data often skews toward populations with resources and regular healthcare contact, potentially overestimating true patient satisfaction across all demographic groups. Safety signals sometimes emerge slowly in continuation patterns. Early continuation rates for a new medication can be high, only to decline sharply once side effects accumulate or long-term risks become apparent. This happened partially with aducanumab, which was discontinued largely due to lack of efficacy evidence and safety concerns despite some early positive signals. A warning: high continuation rates at 12 months don’t predict whether those rates will sustain at 24 or 36 months, particularly as adverse events emerge. Physicians and patients should monitor continuation patterns for the specific therapies they’re considering rather than assuming early success predicts long-term safety and satisfaction.
The Role of Family and Caregiver Satisfaction in Medication Continuation
Family involvement drives many continuation decisions in Alzheimer’s disease, sometimes more than patient preference alone. An adult child who sees their parent receiving infusions for cognitive stabilization may feel satisfied that they’re “doing something” to slow the disease. This satisfaction with treatment action can sustain continuation even if the patient’s explicit preferences might be more ambivalent. Conversely, a caregiver exhausted by treatment logistics might facilitate discontinuation despite solid efficacy data.
These family dynamics don’t negate the value of continuation patterns as satisfaction signals; rather, they complicate them, showing that continuation reflects satisfaction across the whole decision-making system, not just the patient. For example, a spouse managing a partner’s care might experience satisfaction from the structured clinical encounters that come with newer monoclonal antibody infusions—regular contact with specialists, objective neuroimaging assessments, and biological markers of disease progression provide concrete touchpoints. That structural satisfaction can sustain continuation independently of cognitive outcomes, which is a perfectly valid reason for people to continue treatment. Understanding this helps explain why continuation patterns remain robust even when cognitive decline continues.
Future Trajectories—Will Continuation Patterns Remain a Reliable Satisfaction Signal?
As Alzheimer’s treatments expand and evolve, continuation patterns will likely become even more meaningful as differentiation signals. If several disease-modifying therapies become available, patients will increasingly choose between options based on real-world experience. The therapies that retain patients across 24, 36, and 48 months will demonstrate they offer value worth sustaining, while those with declining continuation rates will signal that either efficacy or tolerability falls short of expectations. This natural market-driven sorting will provide increasingly granular data about what different patient populations actually prefer.
The emergence of combination therapies and personalized approaches to Alzheimer’s treatment suggests future continuation patterns will reflect more tailored satisfaction. A patient starting a dual-targeted therapy or combination of monoclonal antibodies will have data-driven reason to continue or adjust based on their specific response profile. Continuation patterns that account for patient genetics, biomarker status, and prior response will become more informative than overall continuation rates. This evolution will move beyond “Is this medication continued?” toward “Which patients continue this medication and why?” That more nuanced understanding will provide physicians and families with clearer guidance about real-world satisfaction and value for different individuals facing Alzheimer’s disease.
Conclusion
Drug continuation patterns in Alzheimer’s disease represent a meaningful, if often overlooked, measure of patient and family satisfaction. When patients persist with treatments despite the disease’s progressive nature, ongoing cognitive decline, and substantial treatment burden, they’re providing evidence that the value of slowing decline outweighs the cost of continuing. This real-world perspective complements clinical trial data and offers hope to families wondering whether disease-modifying therapies are “worth it.” The signal is not perfect—continuation rates don’t eliminate the need for careful efficacy evaluation or ongoing safety monitoring—but they do reflect genuine human judgments about what treatment outcomes mean in the context of actual lives.
Moving forward, patients and families considering Alzheimer’s treatment should view continuation data as one credible source of information about what treatments people actually choose to stay on over time. Ask your neurologist about real-world continuation rates for treatments you’re considering, and ask what factors lead some patients to continue while others discontinue. These conversations honor the real-world experience of people living with and alongside Alzheimer’s disease, whose satisfaction signals matter as much as any clinical trial result.
You Might Also Like
- Outcome Measurement Tools Standardize Alzheimer’s Treatment Assessment
- Investor Conferences Feature Alzheimer’s Treatment Company Presentations
- Food Science Research Investigates Dietary Connections to Alzheimer’s
For more, see NIH MedlinePlus — dementia.
